272 related articles for article (PubMed ID: 29437823)
1. Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia.
Leonard CE; Brensinger CM; Aquilante CL; Bilker WB; Boudreau DM; Deo R; Flory JH; Gagne JJ; Mangaali MJ; Hennessy S
Diabetes Care; 2018 Apr; 41(4):713-722. PubMed ID: 29437823
[TBL] [Abstract][Full Text] [Related]
2. Risk of sudden cardiac arrest and ventricular arrhythmia with sulfonylureas: An experience with conceptual replication in two independent populations.
Dhopeshwarkar N; Brensinger CM; Bilker WB; Soprano SE; Flory JH; Dawwas GK; Gagne JJ; Hennessy S; Leonard CE
Sci Rep; 2020 Jun; 10(1):10070. PubMed ID: 32572080
[TBL] [Abstract][Full Text] [Related]
3. Hypoglycemia in hospitalized patients treated with sulfonylureas.
Deusenberry CM; Coley KC; Korytkowski MT; Donihi AC
Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146
[TBL] [Abstract][Full Text] [Related]
4. Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics.
Leonard CE; Bilker WB; Brensinger CM; Han X; Flory JH; Flockhart DA; Gagne JJ; Cardillo S; Hennessy S
Clin Pharmacol Ther; 2016 May; 99(5):538-47. PubMed ID: 26566262
[TBL] [Abstract][Full Text] [Related]
5. The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.
Leonard CE; Brensinger CM; Dawwas GK; Deo R; Bilker WB; Soprano SE; Dhopeshwarkar N; Flory JH; Bloomgarden ZT; Gagne JJ; Aquilante CL; Kimmel SE; Hennessy S
Cardiovasc Diabetol; 2020 Feb; 19(1):25. PubMed ID: 32098624
[TBL] [Abstract][Full Text] [Related]
6. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
[TBL] [Abstract][Full Text] [Related]
7. Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia.
Zhou M; Wang SV; Leonard CE; Gagne JJ; Fuller C; Hampp C; Archdeacon P; Toh S; Iyer A; Woodworth TS; Cavagnaro E; Panozzo CA; Axtman S; Carnahan RM; Chrischilles EA; Hennessy S
Epidemiology; 2017 Nov; 28(6):838-846. PubMed ID: 28682851
[TBL] [Abstract][Full Text] [Related]
8. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas.
Parekh TM; Raji M; Lin YL; Tan A; Kuo YF; Goodwin JS
JAMA Intern Med; 2014 Oct; 174(10):1605-12. PubMed ID: 25179404
[TBL] [Abstract][Full Text] [Related]
9. Comparative safety of sulfonylureas among U.S. nursing home residents.
Zullo AR; Riester MR; Hayes KN; Munshi MN; Berry SD
J Am Geriatr Soc; 2023 Apr; 71(4):1047-1057. PubMed ID: 36495141
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
[TBL] [Abstract][Full Text] [Related]
11. Individual sulfonylureas and serious hypoglycemia in older people.
Shorr RI; Ray WA; Daugherty JR; Griffin MR
J Am Geriatr Soc; 1996 Jul; 44(7):751-5. PubMed ID: 8675920
[TBL] [Abstract][Full Text] [Related]
12. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
[TBL] [Abstract][Full Text] [Related]
13. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study.
Leonard CE; Han X; Brensinger CM; Bilker WB; Cardillo S; Flory JH; Hennessy S
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):9-18. PubMed ID: 29108130
[TBL] [Abstract][Full Text] [Related]
14. Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis.
Romley JA; Gong C; Jena AB; Goldman DP; Williams B; Peters A
BMJ; 2015 Dec; 351():h6223. PubMed ID: 26643108
[TBL] [Abstract][Full Text] [Related]
15. Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide.
Skoff RA; Waterbury NV; Shaw RF; Egge JA; Cantrell M
J Manag Care Pharm; 2011 Nov; 17(9):664-71. PubMed ID: 22050391
[TBL] [Abstract][Full Text] [Related]
16. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.
Andersson C; Gislason GH; Jørgensen CH; Hansen PR; Vaag A; Sørensen R; Mérie C; Olesen JB; Weeke P; Schmiegelow M; Norgaard ML; Køber L; Torp-Pedersen C
Diabetes Res Clin Pract; 2011 Oct; 94(1):119-25. PubMed ID: 21831467
[TBL] [Abstract][Full Text] [Related]
17. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
[TBL] [Abstract][Full Text] [Related]
18. The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes.
Tuccori M; Wu JW; Yin H; Majdan A; Azoulay L
Diabetes Care; 2015 Nov; 38(11):2083-9. PubMed ID: 26341130
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
[TBL] [Abstract][Full Text] [Related]
20. Rates of hypoglycemia in users of sulfonylureas.
van Staa T; Abenhaim L; Monette J
J Clin Epidemiol; 1997 Jun; 50(6):735-41. PubMed ID: 9250272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
